Alcohol‐Related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study1. Issue 5 (15th January 2019)

• Record Type: Journal Article
• Authors: Szabo, Gyongyi; Kamath, Patrick S.; Shah, Vijay H.; Thursz, Mark; Mathurin, Philippe
• Other Names: investigator.; Addolorato Giovanni investigator.; Bataller Ramon investigator.; Burra Patrizia investigator.; Castera Laurent investigator.; Cortez Pinto Helena investigator.; Diehl Anna Mae investigator.; Gao Bin investigator.; Gilmore Sir Ian investigator.; Hampe Jochen investigator.; Jürgen Rehm investigator.; Karin Michael investigator.; Krag Alexander investigator.; Leon David investigator.; Leptak Christopher investigator.; Louvet Alexandre investigator.; Lucey Michael investigator.; McClain Craig investigator.; Nagy Laura investigator.; Pageaux Georges‐Philippe investigator.; Sanyal Arun investigator.; Schnabl Bernd investigator.; Tiniakos Dina investigator.; Trautwein Christian investigator.; Tsukamoto Hidekazu investigator.
• Is Part Of: Hepatology. Volume 69:Issue 5(2019)
• Page Start: 2271
• Page End: 2283
• Publication Date: 2019-01-15
• Subjects: Heart -- Diseases -- Nursing -- Periodicals; Lungs -- Diseases -- Nursing -- Periodicals; Intensive care nursing -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1002/hep.30369
• Languages: English
• ISSNs: 0270-9139

Abstract

Abstract: A joint meeting of the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) was held in London on September 30 and October 1, 2017. The goals of the meeting were to identify areas of broad agreement and disagreement, develop consensus, and determine future directions to ultimately reduce the burden, morbidity, and mortality of alcohol‐related liver disease (previously termed alcoholic liver disease). The specific aims of the meeting were to identify unmet needs and areas for future investigation, in order to reduce alcohol consumption, develop markers for diagnosis and prognosis of disease, and create a framework to test novel pharmacological agents with pre‐specified treatment endpoints. A table summary of these goals and aims is provided in the context of epidemiology, current management strategies, next steps for future trials and translational science.